IGF2BP1 and hepatocellular carcinoma: Additionally, IGF2BP1 has shown to activate ERK, JNK, and p38 MAPKs, which eventually promoted the progression of hepatocellular carcinoma cells,[51] therefore, we cannot exclude the possibility there is a reciprocal regulatory loop between ERK1/2 and IGF2BP1.